Sarah Y Neshat, Chun Hei Ryan Chan, Jawaun Harris, Osamah M Zmily, Savannah Est-Witte, Johan Karlsson, Sydney R Shannon, Manav Jain, Joshua C Doloff, Jordan J Green, Stephany Y Tzeng
Immuno-oncology therapies have been of great interest with the goal of inducing sustained tumor regression, but clinical results have demonstrated the need for improved and widely applicable methods. An antigen-free method of cancer immunotherapy can stimulate the immune system to recruit lymphocytes and produce immunostimulatory factors without prior knowledge of neoantigens, while local delivery reduces the risk of systemic toxicity. To improve the interactions between tumor cells and cytotoxic lymphocytes, a gene delivery nanoparticle platform was engineered to reprogram the tumor microenvironment (TME) in situ to be more immunostimulatory by inducing tumor-associated antigen-presenting cells (tAPCs) to activate cytotoxic lymphocytes against the tumor...
September 2023: Biomaterials